+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-obesity Prescription Drugs Market by Drug Class, Administration Route, Distribution Channel, End User - Global Forecast to 2030- Product Image
Anti-obesity Prescription Drugs Market by Drug Class, Administration Route, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Anti-obesity Prescription Drugs Market by Drug Class, Administration Route, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904662
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-obesity Prescription Drugs Market grew from USD 6.71 billion in 2024 to USD 7.28 billion in 2025. It is expected to continue growing at a CAGR of 8.15%, reaching USD 10.75 billion by 2030.

A Transformative Era in Anti-Obesity Pharmacotherapy

Obesity has emerged as one of the most pressing public health challenges of the 21st century, with prescription drugs playing an increasingly critical role in comprehensive treatment regimens. Beyond lifestyle modifications and behavioral interventions, the advent of pharmacotherapies has transformed clinical approaches, offering new avenues for sustainable weight loss and metabolic health improvement. As the market matures, stakeholders-from pharmaceutical developers to healthcare providers-must navigate an intricate array of therapeutic classes, administration modes, regulatory changes, and global pricing pressures.

This executive summary distills complex market dynamics into clear, actionable insights. It sets the stage for understanding how innovation in drug mechanisms, shifting policy landscapes, and evolving patient preferences converge to create fresh opportunities. By exploring the factors reshaping the anti-obesity drug market, this report equips decision-makers with the knowledge needed to stay ahead of competitors and deliver meaningful health outcomes.

Pioneering Breakthroughs Fuel Market Evolution

In recent years, the anti-obesity landscape has undergone a fundamental transformation driven by scientific breakthroughs, evolving patient expectations, and heightened investor interest. Glucagon-like peptide-1 receptor agonists have risen to prominence, delivering unprecedented efficacy and igniting a wave of research into novel peptide analogs and combination therapies. Meanwhile, legacy drug classes such as amylin analogs, lipase inhibitors, and serotonin receptor modulators continue to refine their value propositions through formulation improvements and targeted patient segments.

Concurrently, digital health solutions and remote monitoring tools have augmented pharmacotherapy, fostering improved adherence and personalized dosing strategies. These innovations are blurring traditional boundaries between drug and device, creating integrated care pathways that leverage data analytics to optimize outcomes. As the competitive field intensifies, partnerships between biotech start-ups, established pharmaceutical firms, and tech companies are accelerating pipeline development. This collaborative ecosystem is redefining how treatments are discovered, delivered, and scaled, ultimately enhancing access and affordability for patients worldwide.

Navigating Tariff-Driven Cost Pressures in 2025

The impending implementation of tariffs on pharmaceutical imports into the United States is set to reverberate throughout the supply chain, elevating production costs and compelling manufacturers to recalibrate pricing strategies. While raw material sourcing and active pharmaceutical ingredient procurement may experience marginal cost increases, the real impact will manifest in negotiated pricing with payers and wholesale distributors. These shifts could delay formulary inclusions and introduce new rebate structures, straining relationships between suppliers and managed care organizations.

In practical terms, pharmaceutical companies will need to adapt their procurement models, potentially reshoring certain manufacturing processes to mitigate tariff exposure. Strategic inventory management will become imperative, with stakeholders reevaluating buffer stock levels and logistic arrangements. Although end-user price inflation for patients remains a concern, targeted policy interventions and value-based contracting could alleviate some of the burden. As regulatory authorities and industry associations engage in dialogue over tariff exemptions and tariff rate quotas, companies that proactively model multiple cost scenarios will maintain a competitive edge.

Unveiling Layered Segmentation for Strategic Positioning

Understanding the market through the lens of drug class reveals four primary categories shaping therapeutic choices. Amylin analogs, exemplified by pramlintide, offer adjunctive benefits alongside insulin therapies, while the surge of glucagon-like peptide-1 agonists-spanning dulaglutide, exenatide, liraglutide, and semaglutide-has redefined efficacy benchmarks and spurred intense pipeline competition. Orlistat, as the cornerstone of lipase inhibitors, underscores continued demand for gastrointestinal-focused mechanisms, even as serotonin receptor modulators like lorcaserin strive to reclaim regulatory favor through safety refinements.

Equally important is the route of administration, which influences patient adherence and market penetration. Injectable formats, delivered via auto-injectors, prefilled pens, and traditional vials and syringes, cater to patients seeking maximal pharmacologic impact with controlled dosing regimens. Oral therapies, available in capsule and tablet formulations, appeal to those prioritizing convenience and established dosing schedules. Meanwhile, distribution channels span direct sales to large healthcare institutions, hospital inpatient and outpatient pharmacies, specialized online platforms maintained by manufacturers and third-party vendors, and retail environments encompassing both national chains and independent operators. End users range from ambulatory care centers and home healthcare settings to general hospitals and specialty clinics focused on endocrinology, general practice, and dedicated weight loss programs. This multi-dimensional segmentation framework illuminates where growth pockets exist and where companies can tailor their value propositions most effectively.

Decoding Regional Market Complexities

Geographic dynamics play a pivotal role in shaping market trajectories, as regional healthcare priorities, reimbursement frameworks, and patient demographics diverge significantly. In the Americas, robust R&D investments and broad insurance coverage underpin swift adoption of high-efficacy GLP-1 therapies, while ongoing obesity prevalence drives sustained demand for both novel and legacy drugs. Reimbursement complexities in this region necessitate flexible contracting models, with tiered formularies and co-pay assistance programs influencing prescribing behaviors.

In Europe, Middle East & Africa, diverse regulatory landscapes and variable healthcare infrastructure present both challenges and opportunities. Western Europe’s centralized health technology assessment processes often serve as a global benchmark, whereas emerging markets in the Middle East and Africa are witnessing early entries of cost-effective or biosimilar alternatives. Ambitious government-led obesity prevention initiatives are catalyzing partnerships between public health agencies and pharmaceutical firms to pilot integrated care models.

The Asia-Pacific region is characterized by a dual trajectory: mature markets such as Japan and Australia exhibit growing interest in peptide-based therapies supported by favorable reimbursement policies, while developing economies in Southeast Asia and South Asia are focused on localized manufacturing and public-private collaborations to improve drug accessibility. Cross-border trade agreements and regional harmonization efforts will further streamline regulatory approvals, enhancing the speed to market for innovative solutions.

Profiling Leaders and Disruptors in the Pipeline

The competitive landscape is dominated by a handful of innovators that have shaped therapeutic standards and driven market expansion. Leading the charge are companies with strong peptide drug expertise, whose robust pipelines and manufacturing capabilities enable them to capture premium market share and set pricing benchmarks. These market leaders have leveraged extensive clinical trial programs to validate superior weight loss outcomes and cardiovascular benefits, reinforcing their positioning in disease management guidelines.

Meanwhile, agile biotechnology firms and generic drug manufacturers are capitalizing on patent expirations and regulatory windows to introduce cost-effective alternatives and next-generation formulations. Strategic alliances, licensing agreements, and co-promotion deals are prevalent as companies seek to bolster their portfolios and enter new geographic territories. Beyond product innovation, corporate strategies are increasingly focused on digital engagement platforms, patient support programs, and outcome-based contracting to differentiate offerings and foster long-term loyalty.

New entrants, particularly those harnessing novel peptide conjugation techniques and sustained-release technologies, are challenging incumbents by promising enhanced safety profiles and simplified dosing regimens. The interplay of R&D investments, intellectual property landscapes, and manufacturing scalability will determine which players emerge as the next wave of market frontrunners.

Strategic Imperatives for Sustainable Growth

Industry leaders should prioritize integrated approaches that align clinical innovation with patient-centric support mechanisms. This begins with expanding real-world evidence studies to capture long-term safety and efficacy outcomes, thereby strengthening payer negotiations and justifying premium pricing. Concurrently, diversifying distribution strategies-by forging deeper partnerships with online pharmacy platforms and telehealth providers-will enhance reach among digitally engaged patient cohorts.

To mitigate tariff-related cost pressures, companies must adopt agile supply chain models, including dual-sourcing agreements and regional manufacturing hubs, to maintain uninterrupted product availability. Investing in predictive analytics will enable more accurate demand forecasting and inventory optimization, reducing exposure to pricing volatility. Collaboration with regulatory bodies to secure tariff relief or carve-outs for critical therapeutic categories can further alleviate cost burdens.

Moreover, leveraging advanced drug delivery technologies-such as next-generation auto-injectors and oral peptide encapsulations-will address adherence challenges and differentiate offerings. Finally, embedding outcome-based contracting into commercial strategies will align stakeholder incentives, demonstrating measurable health improvements and reinforcing the value proposition for payers and providers alike.

Robust Methodology Anchored in Triangulated Intelligence

The insights in this report are underpinned by a rigorous, multi-phased research approach. Primary research involved in-depth interviews with key stakeholders, including clinician thought leaders, formulary decision-makers, supply chain executives, and patient advocacy representatives. These qualitative engagements provided nuanced perspectives on therapeutic preferences, reimbursement challenges, and emerging pipeline trends.

Secondary research encompassed a comprehensive review of peer-reviewed journals, regulatory filings, patent databases, and government publications to map historical approvals, safety warnings, and labeling changes. Proprietary databases and commercial intelligence platforms were leveraged to analyze competitive positioning, pricing structures, and market share dynamics. Data triangulation across these sources ensured consistency and mitigated information gaps.

Quantitative analysis integrated vendor shipment data, hospital procurement records, and prescription volume trends to validate market movements. Segmentation frameworks were constructed using standardized classification methodologies, enabling cross-regional comparability. Throughout, a robust quality assurance process-comprising peer reviews and editorial checks-guaranteed the accuracy and integrity of all findings.

Charting a Cohesive Path Forward Amid Complexity

As the anti-obesity prescription drug market continues its acceleration, stakeholders who embrace innovation, foster strategic collaborations, and rigorously evaluate cost structures will emerge as frontrunners. The dual imperatives of clinical efficacy and economic value are reshaping how therapies are developed, marketed, and reimbursed. Companies that can seamlessly integrate advanced drug delivery systems, harness real-world evidence, and navigate complex regulatory environments will secure lasting competitive advantages.

Moreover, the interplay of regional nuances-from reimbursement policies in the Americas to capacity building in emerging EMEA markets and manufacturing initiatives in Asia-Pacific-underscores the need for tailored approaches. A one-size-fits-all strategy will fall short in addressing the diverse healthcare ecosystems and patient needs across geographies. By aligning global ambitions with local execution plans, industry players can optimize market access, drive sustainable revenue growth, and ultimately improve patient outcomes in the global fight against obesity.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Amylin Analogs
      • Pramlintide
    • GLP-1 Agonists
      • Dulaglutide
      • Exenatide
      • Liraglutide
      • Semaglutide
    • Lipase Inhibitors
      • Orlistat
    • Serotonin Receptor Modulators
      • Locaserin
  • Administration Route
    • Injectables
      • Auto-Injectors
      • Prefilled Pens
      • Vials And Syringes
    • Orals
      • Capsules
      • Tablets
  • Distribution Channel
    • Direct Sales
    • Hospital Pharmacies
      • Inpatient
      • Outpatient
    • Online Pharmacies
      • Manufacturer Websites
      • Third-Party Platforms
    • Retail Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
  • End User
    • Ambulatory Care Centers
    • Home Care Settings
    • Hospitals
    • Specialty Clinics
      • Endocrinology Clinics
      • General Practice Clinics
      • Weight Loss Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Pfizer Inc.
  • AstraZeneca PLC
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Roche Holding AG
  • Boehringer Ingelheim International GmbH

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-obesity Prescription Drugs Market, by Drug Class
8.1. Introduction
8.2. Amylin Analogs
8.2.1. Pramlintide
8.3. GLP-1 Agonists
8.3.1. Dulaglutide
8.3.2. Exenatide
8.3.3. Liraglutide
8.3.4. Semaglutide
8.4. Lipase Inhibitors
8.4.1. Orlistat
8.5. Serotonin Receptor Modulators
8.5.1. Locaserin
9. Anti-obesity Prescription Drugs Market, by Administration Route
9.1. Introduction
9.2. Injectables
9.2.1. Auto-Injectors
9.2.2. Prefilled Pens
9.2.3. Vials And Syringes
9.3. Orals
9.3.1. Capsules
9.3.2. Tablets
10. Anti-obesity Prescription Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Direct Sales
10.3. Hospital Pharmacies
10.3.1. Inpatient
10.3.2. Outpatient
10.4. Online Pharmacies
10.4.1. Manufacturer Websites
10.4.2. Third-Party Platforms
10.5. Retail Pharmacies
10.5.1. Chain Pharmacies
10.5.2. Independent Pharmacies
11. Anti-obesity Prescription Drugs Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Home Care Settings
11.4. Hospitals
11.5. Specialty Clinics
11.5.1. Endocrinology Clinics
11.5.2. General Practice Clinics
11.5.3. Weight Loss Clinics
12. Americas Anti-obesity Prescription Drugs Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Anti-obesity Prescription Drugs Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Anti-obesity Prescription Drugs Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Novo Nordisk A/S
15.3.2. Eli Lilly and Company
15.3.3. Pfizer Inc.
15.3.4. AstraZeneca PLC
15.3.5. Sanofi S.A.
15.3.6. GlaxoSmithKline plc
15.3.7. Johnson & Johnson
15.3.8. Merck & Co., Inc.
15.3.9. Roche Holding AG
15.3.10. Boehringer Ingelheim International GmbH
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTI-OBESITY PRESCRIPTION DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTI-OBESITY PRESCRIPTION DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THIRD-PARTY PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 85. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 87. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 88. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 90. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 91. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 92. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 93. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 95. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 96. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 97. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 106. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 109. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 110. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 111. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 170. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 172. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 173. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 174. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 175. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 176. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 180. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 181. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 182. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 184. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 186. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 187. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 189. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 190. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 191. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 192. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 194. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 195. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 196. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 212. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 213. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 214. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 215. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 217. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 218. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 219. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 220. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 222. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 223. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 224. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 226. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 228. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 229. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 230. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 231. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 232. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 233. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 234. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 236. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 237. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 238. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 282. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 283. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 284. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2030 (USD MILLION)
TABLE 285. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 287. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 288. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 289. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2030 (USD MILLION)
TABLE 290. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 292. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 293. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 294. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZ

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anti-obesity Prescription Drugs market report include:
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Pfizer Inc.
  • AstraZeneca PLC
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Roche Holding AG
  • Boehringer Ingelheim International GmbH

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.28 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.75 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anti-Obesity Drugs - Global Strategic Business Report - Product Image

Anti-Obesity Drugs - Global Strategic Business Report

  • Report
  • 264 Pages
  • Global
From
Anti-Obesity Therapeutics Market by Treatment Type, Drug Type, Route Of Administration, Drug Formulation, End-User, Distribution Channel - Global Forecast to 2030 - Product Image

Anti-Obesity Therapeutics Market by Treatment Type, Drug Type, Route Of Administration, Drug Formulation, End-User, Distribution Channel - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Anti-Obesity Drugs Market by Product Type, Distribution Channel, End User, Dosage Form - Global Forecast to 2030 - Product Image

Anti-Obesity Drugs Market by Product Type, Distribution Channel, End User, Dosage Form - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Anti-Obesity Drugs Market Size, Share, Trends and Forecast by Drug Class, Drug Type, Distribution Channel, and Region, 2025-2033 - Product Image

Anti-Obesity Drugs Market Size, Share, Trends and Forecast by Drug Class, Drug Type, Distribution Channel, and Region, 2025-2033

  • Report
  • 141 Pages
  • Global
From
Anti-Obesity Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

Anti-Obesity Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 182 Pages
  • Global
From

About the Anti Obesity Prescription Drugs Market

The Anti-Obesity Prescription Drugs market is a segment of the healthcare industry focused on the development, production, and marketing of medication designed to combat obesity. These medications are intended for individuals who are unable to achieve weight loss through diet and exercise alone. Anti-obesity drugs work through various mechanisms, including appetite suppression, increased energy expenditure, and decreased nutrient absorption. The market encompasses a variety of drug classes, such as lipase inhibitors, serotonin receptor agonists, and others, each targeting different pathways related to weight regulation. The use of anti-obesity prescription drugs is typically recommended for those with a body mass index (BMI) above a certain threshold or for overweight individuals with weight-related health conditions such as diabetes or high blood pressure. The development of these pharmacological agents is guided by stringent regulatory standards to ensure their efficacy and safety. Market players invest in research and development to introduce more effective treatments with fewer side effects, as obesity remains a leading health concern. Several companies are key contributors to the Anti-Obesity Prescription Drugs market. Some of the well-known players include Novo Nordisk, GlaxoSmithKline, Roche, and Vivus, Inc. These companies are involved in manufacturing FDA-approved prescription drugs and are engaged in ongoing research to improve existing treatments and bring new solutions to the market. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.